AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05334485 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral starch placebo
Study NCT06546020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Haskap berry smoothie
Description: A smoothie blend of berries and water
Study NCT06546020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: A smoothie with no polyphenolic content and matched in carbohydrate composition to the experimental haskap smoothie
Study NCT06483620 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropathy - and Foot Ulcer - Specific Quality of Life instrument (Neuro Qol)
Description: The NeuroQoL questionnaire is a valid, reliable, and self-reported questionnaire. It has 35-items with six domains namely, painful symptoms and paresthesia (items 1-7), reduction or loss of ability to feel (items 8-10), unsteadiness while walking/standing/diffuse sensory-motor symptoms (items 11-13), limitation in daily living (items 14 - 16), interpersonal problems (items 17-20), emotional distress (items 21- 27) and end with an overall assessment of quality of life or satisfaction with experiences in the above six domains \[1 item in each domains, i.e. additional 6 items (items 28-33)\]. The two final items (items 34-35) assess overall impact of neuropathy on QoL \[5\]. The scoring of the questionnaire is according to a five-point Likert scale, all the time, most of the time, some of the time, occasionally, never. Each domain has a maximum score 5 and minimum 1, where 5 means that the QoL is affected all the time because of the foot problem while 1 means never it affects their QoL
Study NCT05381103 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA-PET and SOC MRI
Description: 60 min continuous acquisition of PET data after 3-6 mCI injection of \[68Ga\]P16-093 followed by contrast-CT
Study NCT05381103 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: SOC MRI
Description: Standard of care MRI
Study NCT05107492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 450mg
Description: following a single subcutaneous dose of PF-06480605 450 mg
Study NCT05107492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150mg
Description: following a single subcutaneous dose of PF-06480605 150 mg
Study NCT05107492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: following a single subcutaneous dose of placebo
Study NCT06123221 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osseodensification with Versah system
Description: Access to the bone crest will be performed through a slightly palatinized crestal incision, and a full-thickness mucoperiosteal flap will be elevated. Implant site preparation will be performed according to the bone densification drilling sequence established by the Densah® technique protocol
Study NCT06123221 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral window
Description: A full-thickness mucoperiosteal flap will be elevated. The lateral window will be made with a spherical diamond drill (number 8) at 20,000 rpm. The mesiodistal and apicocoronal dimensions of the lateral access window to the sinus will be measured in all the participants using a caliper. Sinus membrane elevation will be performed with manual instruments.
Study NCT06164041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The use of mobile applications promoted from the physical education classroom to improve adolescent health.
Description: Before starting the intervention, a total of 465 adolescents participated in pretest measurements (T1).~Researchers in charge of explaining how the apps worked were not involved in the measurements or subsequent analysis, as they knew which student belonged to each App and control group. Once each app had been described and its use explained, a training plan was drawn up to be followed during the period of mandatory use.~The adolescents were motivated to utilize the app for a duration of ten weeks, aiming for a minimum usage of three times per week.~After the mandatory intervention with the mobile apps, post-test measurements were carried out (T2). Then, a period of 10 weeks was provided in which the use of the app was neither mandatory nor promoted from the physical education subject, after which the post-test 2 measurements (T3) were taken.
Study NCT05497479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.003% AR-15512 to be administered in both eyes
Description: Two rounds of Schirmer tests, performed without anesthetic (per randomization), before and after instillation of 0.003% AR-15512
Study NCT05497479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle to be administered in both eyes
Description: Two rounds of Schirmer tests, performed without anesthetic, before and after instillation of Vehicle
Study NCT05497479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.003% AR-15512 to be administered in both eyes
Description: Two rounds of Schirmer tests, performed with anesthetic (per randomization), before and after instillation of 0.003% AR-15512
Study NCT05497479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle to be administered in both eyes
Description: Two rounds of Schirmer tests, performed with anesthetic (per randomization), before and after instillation of Vehicle
Study NCT06293209 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3M cold pack
Description: 3M cold pack
Study NCT05294692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Health Incentives
Description: Caterpillar Health (Caterpillar Health Inc., Leeds, UK) is a multi-component healthy living app that includes financial incentive (points redeemable for consumer goods like movies or gym passes) and was made available to Leeds, UK residents on the Apple iTunes/App Store and Google Play app stores on August 8, 2022. The app was later made available to all of the UK as of October 3, 2022. The app uses the smartphone's in-built accelerometer and/or is integrated with Apple Health and Google Fit to promote physical activity through step tracking. To offer a variety of popular incentives, Caterpillar Health formed partnerships with two major UK based companies, Vue Cinema and Hussle (a gym network system), allowing users to redeem points for free movie and gym passes. Additionally, the company collaborated with a UK health agency (Active Leeds via Leeds City Council) to assist in the development and approval of educational health quiz content.
Study NCT05521698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO
Study NCT05521698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT05521698 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT05521698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection
Study NCT05521698 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection
Study NCT05521698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT05521698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05521698 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05220670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT
Description: It will be carried out after a 10-minute warm-up period with joint mobility exercises and dynamic stretching. The intervention will consist of a training in which intense work intervals and active rest periods are combined using a cycle ergometer. The session will be divided into 4 intervals of 4 minutes duration at an intensity of 85-95% of the maximum heart rate \[MHR\], individually controlled during all sessions (Polar Team pro®), followed by active rest intervals of 3 minutes duration at 50-70% FCM. After training, a 10-minute cool-down of gentle pedaling and joint range exercises will be carried out.
Study NCT05220670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MICT
Description: Heating phase identical to the previous one. Subsequently, the participants will perform training on the cycle ergometer with an intensity close to 70% FCM maintained for 40 minutes and will be individually controlled (Polar Team pro®). The session will conclude with a cool-down phase identical to the previous one.
Study NCT05521698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of Bladder Tumor
Description: Undergo TURBT
Study NCT05521698 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transurethral Resection of Bladder Tumor
Description: Undergo TURBT
Study NCT05139303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthoapnea NOA®
Description: The efficacy of the appliance for the management of OSA will be stablished based on two criteria. Criterion I: > 50% reduction of AHI/RDI. Criterion II: AHI/RDI \< 5 events/hour or \<15 events/hour with a significative reduction of OSA associates symptoms as defined before. Therapeutic failure will be established when at 100% of advancement of the device, there is less than 50% of reduction of the AHI/RDI with a residual AHI/RDI >5 events/hour with OSA associates symptoms.
Study NCT04916626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPUS YOUNG
Description: OPUS YOUNG is a two year out-patient specialized early intervention service for children and adolescents with a first episode psychosis. The OPUS YOUNG treatment consists of the following elements: modified assertive community treatment, low patients to case manager ratio, cognitive-behavioural case management (CBCM), psycho-educational family treatment including multiple family groups(MFG) and psychoeducational siblings groups, Social Cognition and Interaction Training (SCIT), possible individual Cognitive Behavioural Therapy (CBT) in addition to CBCM, and manual based psychopharmacologic treatment. Additional, special transition support, individual school/employment support, and prevention and treatment of substance abuse.
Study NCT04916626 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The patients allocated to TAU will be offered non-manualized treatment following national Danish guidelines and local guidelines. Treatment is provided by a multidisciplinary team and consists of case-management (no defined upper case load), family support and psychoeducation, in addition to psychopharmacological treatment. In some cases, social skills training and CBT may be offered. In general, office visits take place in outpatient clinics.
Study NCT05308199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thoracic manipulation
Description: thoracic manipulation for unlocking of facet joints
Study NCT06293209 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perskindol cold spray
Description: Perskindol cold spray
Study NCT06293209 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04707625 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept Ophthalmic
Description: Anti-vascular endothelial growth factor intraocular injection
Study NCT06166745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensi-IP toothpaste
Description: Brushing daily with the Sensi-IP toothpaste for 14 days for dentinal hypersensitivity.
Study NCT05734963 — intervention group
Intervention type: GENETIC
Intervention: DNA sequencing, RNA gene expression analysis, molecular profiling
Description: Growth of organoids from tissue samples, collection of tissue, blood and saliva samples for DNA sequencing, RNA gene expression analysis, molecular profiling
Study NCT06225102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kegel Exercise
Description: * Before teaching Kegel exercises, it was recommended that the person empty his bladder and wear comfortable clothing.~* It was said that the person should extend his legs straight while exercising and not to contract his leg, hip and abdominal muscles and not to hold his breath while the pelvic floor muscles contract.~* The relevant muscles were told to contract for 10 seconds and then relax for 10 seconds. The person was also asked to do the exercises during daily activities.~* Exercise was implemented regularly 3 times a day (minimum 30-45 exercises) in the morning, noon and evening.
Study NCT04670900 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tension band wiring or plate fixation
Description: Choice of operative treatment is TBW or PF with a precontoured anatomical plate. The treating surgeon decides if TBW or PF is chosen as operative treatment method. The surgeries are performed according to OTA principles by an experienced surgeon, a trauma fellow or a consultant as approved by the participating hospitals.
Study NCT04670900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active non-operative treatment with optional plaster cast
Description: Patients allocated to non-operative treatment are offered a back-slab in 60 degrees of flexion for pain-relief. The back-slab is removed 7-14 days following injury.
Study NCT05727722 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a single course of micro-encapsulated hepatocytes intraperitoneal transplantation therapy
Description: A single course will be divided into an accelerated titration design phase and a 3+3 design phase to reduce the number of subjects exposed to potentially ineffective doses that may not benefit from treatment. The accelerated titration design phase starts at a starting dose of 0.15x10\^9, moving to the 3+3 design phase at the dose of 0.5x10\^9. According to the semi-logarithmic incremental (10\^0.5-fold) approach, the treatment dosage was set into four groups at a maximum dose of 4.5×10\^9 (allowing for a ±20% difference between the actual dose and the planned dose, considering production specifics). The number or the incremental ratio of subsequent dose groups can be adjusted based on the evaluation of available data in the study, and intermediate doses can be explored.
Study NCT06166745 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride Toothpaste
Description: Brushing daily with the Sodium Fluoride toothpaste for 14 days for dentinal hypersensitivity.
Study NCT06011772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Description: Given IM
Study NCT06011772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV
Study NCT06011772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT06011772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT06011772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT06011772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study NCT06011772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT06011772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Description: Undergo metastasectomy
Study NCT06011772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen collection
Description: Undergo collection of blood samples
Study NCT06011772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06011772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumbab
Description: Given IV
Study NCT05308199 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: muscle enegy technique
Description: to release muscle spasm of cervical musces
Study NCT04955379 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EQ103
Description: Ophthalmic Refractometer with a measurement and background channel
Study NCT05518942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sensorimotor rhythm neurofeedback training
Description: In this study, baseline brain waves will be recorded for 5 minutes before each treatment, and the average value of SMR waves was used as the basis for setting the treatment threshold for the week. During the treatment, the subjects are arranged to sit in front of a computer screen with a game or animation playing. The individual focuses on the games or animations on the screen. The software will analyze the brain wave signals from the brain and convert them into visual and auditory feedback on the computer screen. Clients can learn to control brain activity and give visual and auditory feedback when a set threshold is reached
Study NCT05128643 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant novel coronavirus vaccine (CHO cell)
Description: Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant novel coronavirus vaccine (CHO cells).
Study NCT05216952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate Tablets
Description: 90mg (three 30mg tablets) administered orally once
Study NCT05216952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol Pill
Description: 800mcg (four 200mcg pills) administered vaginally once 6-18 hours following ulipristal acetate
Study NCT05115448 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bevel Position
Description: During 6 dialysis sessions, cannulation was applied to the patients with the direction of the arterial needle in the antegrade direction and the conical tip facing upwards. In the next 6 dialysis sessions, cannulation was applied to the patients in an antegrade direction and with the conical tip facing down.
Study NCT04211064 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasonographic measurement of optic nerve sheath diameter
Description: Optic nerve sheath diameter will be measured at both neuromuscular blocks level.
Study NCT04211064 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonographic measurement of optic nerve sheath diameter
Description: Optic nerve sheath diameter will be measured at both neuromuscular blocks level.
Study NCT04211064 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Deep neuromuscular block
Description: Deep neuromuscular block will be obtained via appropriate dose of rocuronium.
Study NCT04211064 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Moderate neuromuscular block
Description: Moderate neuromuscular block will be obtained via appropriate dose of rocuronium.
Study NCT05015816 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Total body photography
Description: 3 monthly TBP imaging
Study NCT04423822 — intervention group
Intervention type: OTHER
Intervention: stress test
Description: endurance capacity
Study NCT04230421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Monsenso system with feedback
Description: See description under intervention
Study NCT04230421 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Monsenso system without feedback
Description: See description under intervention
Study NCT04230421 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAG Bipola and mood monitoring only
Description: See description under intervention
Study NCT05180292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 MG
Description: Carvedilol 12.5 mg
Study NCT06256289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100mg Tab
Description: Canagliflozin 100mg once daily combined Metformin 1000mg twice daily
Study NCT06256289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Metformin 1000mg twice daily
Study NCT06256289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: Metformin 1000mg twice daily
Study NCT05087381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FluvoxaMINE Maleate 50 MG
Description: The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs.